Prior to joining ViDAC Pharma in late 2012, Dr. Behar served as the Vice President of Biology at Dynamix Pharmaceuticals, a private pharmaceutical company focused on the discovery and development of novel, targeted, small molecule drugs for cancer and auto-immune therapies. In that capacity, Dr. Behar led all biological and pharmacological aspects of the company’s drug pipeline including target selection, and all pre-clinical development. Prior to Dynamix, Dr. Behar worked with Third Rock Ventures as a technology scout, and before that as the Chief Scientist at Quantomix. Dr. Behar also served as a research scientist at Pfizer in Cambridge, MA. Dr. Behar earned her PhD in Molecular Pharmacology from the Division of Medical Sciences at Harvard University where she was awarded the prestigious Ryan Fellowship, and her BSc and MSc and MBA from the Hebrew University in Jerusalem.